EA202092964A1 - Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака - Google Patents
Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении ракаInfo
- Publication number
- EA202092964A1 EA202092964A1 EA202092964A EA202092964A EA202092964A1 EA 202092964 A1 EA202092964 A1 EA 202092964A1 EA 202092964 A EA202092964 A EA 202092964A EA 202092964 A EA202092964 A EA 202092964A EA 202092964 A1 EA202092964 A1 EA 202092964A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- platinum
- cancer
- antineoplastic agents
- basis
- treatment
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229910052697 platinum Inorganic materials 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 abstract 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382432 | 2018-06-18 | ||
| PCT/IB2019/000812 WO2019243900A2 (en) | 2018-06-18 | 2019-06-17 | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092964A1 true EA202092964A1 (ru) | 2021-03-30 |
Family
ID=62837845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092964A EA202092964A1 (ru) | 2018-06-18 | 2019-06-17 | Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210187106A1 (enExample) |
| EP (1) | EP3806899A2 (enExample) |
| JP (2) | JP7379390B2 (enExample) |
| KR (1) | KR20210022065A (enExample) |
| CN (1) | CN112955178B (enExample) |
| AU (2) | AU2019291307B2 (enExample) |
| CA (1) | CA3103369A1 (enExample) |
| EA (1) | EA202092964A1 (enExample) |
| IL (1) | IL279444A (enExample) |
| MA (1) | MA52300A (enExample) |
| SG (1) | SG11202012576QA (enExample) |
| WO (1) | WO2019243900A2 (enExample) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| CA2958685A1 (en) * | 2014-09-10 | 2016-03-17 | The Regents Of The University Of California | Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies |
| EP3283886B1 (en) * | 2015-04-17 | 2020-01-15 | Eisai Inc. | Methods for treating lung cancer |
| WO2018115960A1 (en) * | 2016-12-19 | 2018-06-28 | Mosaic Biomedicals, S.L. | Antibodies against lif and uses thereof |
| KR20210008514A (ko) * | 2018-05-14 | 2021-01-22 | 메디뮨 리미티드 | Lif에 대한 항체 및 이의 투여 형태 |
-
2019
- 2019-06-17 EA EA202092964A patent/EA202092964A1/ru unknown
- 2019-06-17 KR KR1020217001441A patent/KR20210022065A/ko not_active Ceased
- 2019-06-17 US US17/252,449 patent/US20210187106A1/en not_active Abandoned
- 2019-06-17 CA CA3103369A patent/CA3103369A1/en active Pending
- 2019-06-17 EP EP19782687.8A patent/EP3806899A2/en active Pending
- 2019-06-17 WO PCT/IB2019/000812 patent/WO2019243900A2/en not_active Ceased
- 2019-06-17 CN CN201980053679.1A patent/CN112955178B/zh active Active
- 2019-06-17 JP JP2020570163A patent/JP7379390B2/ja active Active
- 2019-06-17 AU AU2019291307A patent/AU2019291307B2/en active Active
- 2019-06-17 MA MA052300A patent/MA52300A/fr unknown
- 2019-06-17 SG SG11202012576QA patent/SG11202012576QA/en unknown
-
2020
- 2020-12-14 IL IL279444A patent/IL279444A/en unknown
-
2023
- 2023-11-01 JP JP2023187689A patent/JP7603772B2/ja active Active
-
2024
- 2024-07-01 AU AU2024204564A patent/AU2024204564A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024204564A1 (en) | 2024-07-18 |
| KR20210022065A (ko) | 2021-03-02 |
| AU2019291307A1 (en) | 2021-02-04 |
| WO2019243900A2 (en) | 2019-12-26 |
| EP3806899A2 (en) | 2021-04-21 |
| AU2019291307B2 (en) | 2024-04-04 |
| JP2024023212A (ja) | 2024-02-21 |
| JP2021533084A (ja) | 2021-12-02 |
| JP7603772B2 (ja) | 2024-12-20 |
| CA3103369A1 (en) | 2019-12-26 |
| IL279444A (en) | 2021-01-31 |
| MA52300A (fr) | 2021-04-21 |
| WO2019243900A3 (en) | 2020-03-05 |
| CN112955178A (zh) | 2021-06-11 |
| US20210187106A1 (en) | 2021-06-24 |
| SG11202012576QA (en) | 2021-01-28 |
| CN112955178B (zh) | 2025-03-11 |
| JP7379390B2 (ja) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125356T1 (el) | Παραγωγα ν-πυριδινυλιου ως αναστολεις της οδου σηματοδοτησης wnt | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| CY1125116T1 (el) | Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου | |
| PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
| MX2022005360A (es) | Inhibidores de ras. | |
| MX2022005359A (es) | Inhibidores de ras. | |
| MX2022005357A (es) | Inhibidores de ras. | |
| EA202092000A1 (ru) | Ингибиторы димеризации egfr и их использование | |
| EA202191852A1 (ru) | Необратимые ингибиторы взаимодействия менин-mll | |
| CY1122243T1 (el) | Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt | |
| DK3902547T3 (da) | Csf1r-hæmmere til anvendelse i cancerbehandling | |
| MX2019013858A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| EA201992497A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| MX391470B (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| DK3890740T3 (da) | CD70 og venetoclax, en BCL-2 inhibitor, kombinationsterapi til behandling af akut myeloid leukæmi | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| EP4585273A3 (en) | Mechanism of resistance to bet bromodomain inhibitors | |
| MX2021004598A (es) | Inhibidores selectivos de rgmc y el uso de los mismos. | |
| CY1124123T1 (el) | Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου | |
| NZ755004A (en) | Antibodies against lif and uses thereof | |
| MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
| EP3562803C0 (en) | Notch inhibitors intended for use in the treatment of acute T-lymphoblastic leukemia | |
| JOP20210216A1 (ar) | علاج السرطان |